GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intellia Therapeutics Inc (LTS:0JBU) » Definitions » Credit Losses Provision

Intellia Therapeutics (LTS:0JBU) Credit Losses Provision


View and export this data going back to 2018. Start your Free Trial

What is Intellia Therapeutics Credit Losses Provision?

Credit Losses Provision only applies to banks.


Intellia Therapeutics (LTS:0JBU) Business Description

Traded in Other Exchanges
Address
40 Erie Street, Suite 130, Cambridge, MA, USA, 02139
Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.